Research progress on antibacterial activity,resistance,pharmacokinetics characteristics and clinical efficacy of omadacycline
Due to the increasingly severe situation of pathogen resistance,the efficacy of classical antibiotics has declined,and the difficulty of treating community-acquired pneumonia(CAP)has gradually increased.Omadacycline was approved for marketing in China in December 2021 and has been approved for treating community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection in adults.Based on introducing the pathogen resistance of CAP,this article systematically reviews the antibacterial activity and resistance,pharmacokinetic characteristics,and clinical efficacy of omadacycline.It is found that its antibacterial spectrum is wide,its bioavailability is high,and its safety is good.Its pharmacokinetic parameters are not affected by the patients'age,gender,liver and kidney function,or drug interactions,and it is effective against multiple drug-resistant bacteria.Gram-negative bacteria producing extended-spectrum β-lactases,atypical pathogens,etc.It can be used as one of the treatment options for CAP.However,due to limited clinical research data and the short clinical application time of the drug,more clinical studies are still needed to verify its efficacy as a monotherapy or in combination with other antibiotics for severe pneumonia patients.
万方数据
